

Matthew A Ciorba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6059415/publications.pdf>

Version: 2024-02-01

74
papers

4,260
citations

186265

28
h-index

123424

61
g-index

78
all docs

78
docs citations

78
times ranked

8437
citing authors

#	ARTICLE	IF	CITATIONS
1	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. <i>Science Immunology</i> , 2020, 5, .	11.9	811
2	Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays. <i>Gut</i> , 2015, 64, 911-920.	12.1	410
3	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2. <i>Annals of Internal Medicine</i> , 2021, 174, 1572-1585.	3.9	273
4	Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. <i>Gut</i> , 2012, 61, 829-838.	12.1	210
5	IDO1 Metabolites Activate β -catenin Signaling to Promote Cancer Cell Proliferation and Colon Tumorigenesis in Mice. <i>Gastroenterology</i> , 2013, 145, 416-425.e4.	1.3	153
6	IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis. <i>Cancer Research</i> , 2019, 79, 1138-1150.	0.9	136
7	A Gastroenterologist's Guide to Probiotics. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 960-968.	4.4	126
8	<i>Debaryomyces</i> is enriched in Crohn's disease intestinal tissue and impairs healing in mice. <i>Science</i> , 2021, 371, 1154-1159.	12.6	126
9	<i>Lactobacillus rhamnosus</i> CG protects the intestinal epithelium from radiation injury through release of lipoteichoic acid, macrophage activation and the migration of mesenchymal stem cells. <i>Gut</i> , 2019, 68, 1003-1013.	12.1	122
10	Indoleamine 2,3 dioxygenase in intestinal disease. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 146-152.	2.3	118
11	Serum Analysis of Tryptophan Catabolism Pathway: Correlation With Crohn's Disease Activity. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1214-1220.	1.9	117
12	Induction of IDO-1 by Immunostimulatory DNA Limits Severity of Experimental Colitis. <i>Journal of Immunology</i> , 2010, 184, 3907-3916.	0.8	100
13	Epithelial Indoleamine 2,3-Dioxygenase 1 Modulates Aryl Hydrocarbon Receptor and Notch Signaling to Increase Differentiation of Secretory Cells and Alter Mucus-Associated Microbiota. <i>Gastroenterology</i> , 2019, 157, 1093-1108.e11.	1.3	92
14	Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. <i>Experimental Hematology</i> , 2019, 80, 36-41.e3.	0.4	90
15	Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 402-409.	1.3	88
16	Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1471-1480.	1.9	88
17	Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. <i>Translational Research</i> , 2016, 167, 67-79.	5.0	79
18	Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2018, 155, 815-828.	1.3	75

#	ARTICLE	IF	CITATIONS
19	Butyrate and Mucosal Inflammation: New Scientific Evidence Supports Clinical Observation. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e108.	2.5	63
20	Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 451-464.	3.4	63
21	Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1569-1576.	1.9	50
22	Enterotoxigenic <i>Escherichia coli</i> blood group A interactions intensify diarrheal severity. <i>Journal of Clinical Investigation</i> , 2018, 128, 3298-3311.	8.2	45
23	Dynamic immunoglobulin responses to gut bacteria during inflammatory bowel disease. <i>Gut Microbes</i> , 2020, 11, 405-420.	9.8	44
24	Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 187-197.	1.3	43
25	Highly conserved type 1 pili promote enterotoxigenic <i>E. coli</i> pathogen-host interactions. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005586.	3.0	42
26	Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. <i>Supportive Care in Cancer</i> , 2020, 28, 5059-5073.	2.2	40
27	Blood Group O-Dependent Cellular Responses to Cholera Toxin: Parallel Clinical and Epidemiological Links to Severe Cholera. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 95, 440-443.	1.4	38
28	Hyaluronic Acid Binding to TLR4 Promotes Proliferation and Blocks Apoptosis in Colon Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2446-2456.	4.1	34
29	De-novo Inflammatory Bowel Disease After Bariatric Surgery: A Large Case Series. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 452-457.	1.3	29
30	Patient-derived small intestinal myofibroblasts direct perfused, physiologically responsive capillary development in a microfluidic Gut-on-a-Chip Model. <i>Scientific Reports</i> , 2020, 10, 3842.	3.3	29
31	IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype. <i>PLoS ONE</i> , 2014, 9, e115848.	2.5	28
32	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388.	3.0	26
33	A Potential Role for Stress-Induced Microbial Alterations in IgA-Associated Irritable Bowel Syndrome with Diarrhea. <i>Cell Reports Medicine</i> , 2020, 1, 100124.	6.5	24
34	Self-reported sleep disturbance in Crohn's disease is not confirmed by objective sleep measures. <i>Scientific Reports</i> , 2020, 10, 1980.	3.3	24
35	Kynurenine pathway metabolites: relevant to vitamin B-6 deficiency and beyond. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 863-864.	4.7	21
36	Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e87-e88.	1.9	21

#	ARTICLE	IF	CITATIONS
37	CEACAMs serve as toxin-stimulated receptors for enterotoxigenic <i>Escherichia coli</i> . Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29055-29062.	7.1	21
38	Hyaluronic acid promotes Lgr5 ⁺ stem cell proliferation and crypt fission through TLR4 and PGE ₂ transactivation of EGFR. American Journal of Physiology - Renal Physiology, 2020, 319, G63-G73.	3.4	20
39	Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial. Clinical Colorectal Cancer, 2021, 20, e185-e193.	2.3	20
40	Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. Clinical Gastroenterology and Hepatology, 2019, 17, 2816-2818.	4.4	19
41	Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1089-1097.	1.9	19
42	Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 816-825.	1.9	18
43	Goblet cell LRRC26 regulates BK channel activation and protects against colitis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
44	A Role for Salivary Peptides in the Innate Defense Against Enterotoxigenic <i>Escherichia coli</i> . Journal of Infectious Diseases, 2018, 217, 1435-1441.	4.0	13
45	Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome. PLoS ONE, 2019, 14, e0213108.	2.5	13
46	The LRRC family of BK channel regulatory subunits: potential roles in health and disease. Journal of Physiology, 2022, 600, 1357-1371.	2.9	13
47	Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1554-1561.	1.9	12
48	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1917-1925.	1.9	11
49	Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. Translational Research, 2021, 231, 124-138.	5.0	11
50	Reg4 Interacts with CD44 to Regulate Proliferation and Stemness of Colorectal and Pancreatic Cancer Cells. Molecular Cancer Research, 2022, 20, 387-399.	3.4	11
51	Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. Leukemia, 2022, 36, 292-295.	7.2	10
52	Nonmicrobial Activation of TLRs Controls Intestinal Growth, Wound Repair, and Radioprotection. Frontiers in Immunology, 2020, 11, 617510.	4.8	10
53	Stem cell and niche regulation in human short bowel syndrome. JCI Insight, 2020, 5, .	5.0	7
54	WIRELESS CAPSULE ENDOSCOPY IN THE DIAGNOSIS OF SMALL BOWEL CROHN'S DISEASE. Inflammatory Bowel Diseases, 2003, 9, 276.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Probiotic Gut Bacteria Enhance Cancer Immunotherapy in a Mouse Model of Melanoma. <i>Gastroenterology</i> , 2016, 151, 206-207.	1.3	6
56	Current and Prospective Methods for Assessing Anti-Tumor Immunity in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4802.	4.1	6
57	Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 677-685.	1.9	5
58	Mesalamine Reduces Intestinal ACE2 Expression Without Modifying SARS-CoV-2 Infection or Disease Severity in Mice. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 318-321.	1.9	5
59	Reactogenicity of the Messenger RNA SARS-CoV-2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. <i>Arthritis Care and Research</i> , 2022, 74, 1953-1960.	3.4	5
60	Postprandial Chylomicron Output and Transport Through Intestinal Lymphatics Are Not Impaired in Active Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 1955-1957.e2.	1.3	4
61	Progress in PD-1-based Immunotherapy: New Mechanistic Insight May Provide Expanded Hope for Application to Colon and Gastrointestinal Cancers. <i>Gastroenterology</i> , 2017, 153, 1162-1163.	1.3	3
62	Serotonin Receptors Regulate Inflammatory Response in Experimental Colitis. <i>Journal of Nutrition</i> , 2020, 150, 1678-1679.	2.9	3
63	Scap and the intestinal epithelial stem cell niche: new insights from lipid biology. <i>Journal of Lipid Research</i> , 2015, 56, 1381-1382.	4.2	2
64	Pneumococcal Disease in Inflammatory Bowel Disease: Justification to Vaccinate at Diagnosis. <i>Gastroenterology</i> , 2016, 151, 365-366.	1.3	2
65	Preliminary results of a phase II study of retifanlimab (PD-1 inhibitor) plus or minus epacadostat (IDO1) Tj ETQq1 1 0.784314 rgBT /Over glioblastoma: NCT03532295.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2058-2058.	1.6	2
66	Advances in understanding and improving gastrointestinal symptoms during supportive and palliative care. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 149-151.	1.3	1
67	Reducing Fluoroquinolone Use Is a Key Step in Controlling the Burden of Clostridium difficile Infection. <i>Gastroenterology</i> , 2017, 153, 606-607.	1.3	1
68	Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions. <i>Crohn's & Colitis 360</i> , 2020, 2, otaa019.	1.1	1
69	Reply to the Letter to the Editor: Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e46-e46.	1.9	1
70	Adding Fuel to The Fire? A Role of Intraepithelial Lymphocytes in Enteric Immune Responses to SARS-CoV-2 Infection. <i>Gastroenterology</i> , 2021, , .	1.3	1
71	Adding Fuel to The Fire? A Role of Intraepithelial Lymphocytes in Enteric Immune Responses to SARS-CoV-2 Infection. <i>Gastroenterology</i> , 2021, , .	1.3	1
72	Research poster preparation for the GI fellow: basics and beyond. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 467-468.	1.0	0

#	ARTICLE	IF	CITATIONS
73	Not So Smart? Artificial Intelligence May Need to Go Deeper to Predict Colorectal Cancer Invasion Depth. <i>Gastroenterology</i> , 2021, , .	1.3	0
74	Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4168-TPS4168.	1.6	0